Diabetes drug target PPARγ rejuvenates aging ovaries in mice

A metabolic signaling pathway best known for its role in diabetes drugs may hold a key to one of biology’s most stubborn problems: the decline of female fertility with age. In a study published in the Journal of Ovarian Research, a team of Korean reproductive scientists reports that activating a nuclear receptor called PPARγ in the ovaries of aged mice improved follicle numbers, oocyte quality, and even blastocyst development after in vitro fertilization. The findings point to a previously underappreciated link between metabolic signaling and the hormonal machinery that governs the ovarian reserve, and they arrive at a moment when demand for age-related fertility interventions is rising worldwide.

The central molecule in the study is anti-Müllerian hormone, or AMH, a glycoprotein produced by granulosa cells of growing follicles. AMH has long served clinicians as a blood biomarker of ovarian reserve, but it is far more than a passive readout. It is a key regulator of primordial follicle activation, restraining the recruitment of resting follicles into the growing pool and thereby helping to maintain the reserve over a female’s reproductive lifespan. What has remained unclear, the authors note, is which upstream pathways connect metabolic signaling to AMH regulation. Because ovarian aging is tightly intertwined with metabolic decline, that missing link matters enormously.

The researchers focused on peroxisome proliferator-activated receptor gamma, PPARγ, a nuclear receptor that acts as a ligand-activated transcription factor controlling genes involved in lipid metabolism and glucose homeostasis. PPARγ is the molecular target of thiazolidinediones, the class of insulin-sensitizing drugs that includes rosiglitazone. Crucially for this study, PPARγ is also expressed in ovarian granulosa cells and has been implicated in follicle development. The team hypothesized that activating this receptor would regulate AMH expression and, through it, the dynamics of primordial follicle regulation in the ovary.

To test the idea, the researchers combined three complementary experimental systems. Ovaries from 2-day-old neonatal mice were cultured ex vivo for up to 96 hours under control conditions or with rosiglitazone treatment. In parallel, 1-day-old neonatal mice were treated in vivo and analyzed seven days later. To capture age-dependent effects, young adult females aged 7 to 8 weeks and aged females aged 56 to 62 weeks received repeated treatment over a 21-day period, followed by ovulation induction, oocyte retrieval, and in vitro fertilization. Molecular, histological, and functional outcomes were assessed at predefined time points, and human granulosa-like cells were analyzed in vitro to check whether the signaling responses were conserved across species.

The molecular results were strikingly specific. PPARγ activation increased Amh expression together with the expression of AMH-associated transcription factors, including Sf1, Gata4, and Foxl2, without altering PPARγ mRNA levels, with statistical significance at P less than 0.05. Sf1, also known as Nr5a1, Gata4, and Foxl2 form the transcriptional circuitry that granulosa cells use to maintain AMH production, so the coordinated upregulation suggests PPARγ acts on the regulatory network rather than on a single gene in isolation. These responses were consistently observed across independent biological replicates, which the authors say supports the robustness and reproducibility of the signaling effects.

Even more intriguing was the pathway the team identified downstream of PPARγ. Activation selectively enhanced phosphorylation of STAT3 at serine 727, both in mouse ovaries and in human granulosa-like cells, at P less than 0.01. Total STAT3 abundance and phosphorylation at tyrosine 705, the site classically associated with cytokine-driven transcription, remained unchanged. This selectivity is technically meaningful: serine 727 phosphorylation modulates STAT3’s transcriptional activity independently of the canonical Tyr705 pathway, implying that PPARγ engages a metabolic branch of STAT3 signaling in granulosa cells. The consistency of this response across mouse and human cell systems strengthens the case that the mechanism is not a rodent quirk.

The functional outcomes in aged mice are what will make the study travel far beyond specialist journals. After repeated rosiglitazone treatment over 21 days, aged females showed increased primordial follicle numbers and reduced zona pellucida remnants, the microscopic debris of degenerated follicles that accumulates as the ovary ages. Treatment also improved oocyte quality and blastocyst development after in vitro fertilization, with significance at P less than 0.05. In young mice, by contrast, treatment effects were minimal, indicating an age-dependent responsiveness to PPARγ activation. The aged animals, whose ovaries were in metabolic and functional decline, were the ones that benefited.

That age-dependent pattern carries both promise and caution. On the promise side, it suggests that PPARγ modulation acts on a reserve that has become dysregulated with age, potentially restoring restraint on primordial follicle activation through the AMH pathway rather than creating new eggs. On the caution side, the authors are explicit that mice and a human granulosa-like cell line were studied without any genetic manipulation of PPARγ, and that caution is warranted when extrapolating the results to clinical contexts. Rosiglitazone itself has a complicated clinical history, having been restricted in some markets over cardiovascular safety concerns, so any translation to human fertility treatment would require careful dose, safety, and efficacy studies.

The study’s design also deserves attention for what it avoided. Rather than overexpressing or deleting PPARγ, the researchers used pharmacological activation in intact ovaries, ex vivo and in vivo, which preserves the natural cellular context of granulosa cells, oocytes, and stromal compartments. The combination of ex vivo neonatal ovary culture, in vivo neonatal and aged mouse models, and in vitro human granulosa-like cell analyses allowed the team to triangulate the mechanism from several angles. All animal experiments were approved by the Institutional Animal Care and Use Committee of CHA University, and the work was funded by the Korean Health Technology R&D Project through KHIDI and by a National Research Foundation of Korea grant.

For a field searching for interventions that slow ovarian aging, the findings support a regulatory role for PPARγ in linking metabolic signaling to AMH regulation and early follicle dynamics, providing mechanistic insights into age-dependent changes in ovarian function. The next questions are predictable: whether the STAT3 Ser727 branch can be targeted more precisely than PPARγ itself, whether the improved blastocyst rates translate into live births, and whether aged human ovaries respond the way aged mouse ovaries did. What is already clear is that the boundary between metabolism and reproductive aging is thinner than once believed, and that a drug class designed for insulin resistance may have something to say about the biology of the biological clock.

Subject of Research: Reproductive biology

Article Title: PPARγ modulation enhances ovarian function and oocyte competence in aged mice

Article References: Park, M. S., Hwang, J. Y., Kim, J. H., Yoon, J. A., Eum, J. H., Lee, W. S., & Yoon, S. Y. (2026). PPARγ modulation enhances ovarian function and oocyte competence in aged mice. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02314-4

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02314-4

Keywords: PPARγ, anti-Müllerian hormone, ovarian reserve, ovarian aging, oocyte quality, rosiglitazone, STAT3 signaling, in vitro fertilization, granulosa cells, Journal of Ovarian Research, PPAR, modulation